Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 34, Issue 3, Pages 553-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2020.01.004
Keywords
Acute myeloid leukemia (AML); Leukemic stem cell (LSC); BPDCN; CD123; Targeted therapy
Categories
Funding
- NIH [R01 CA234478]
- Cellectis
Ask authors/readers for more resources
Hematopoiesis is a tightly regulated process that originates from highly specialized cells, hematopoietic stem cells (HSCs). Many cancers can arise and be maintained by malignant stem cells. In acute myeloid leukemia, leukemic stem cells (LSCs) are identified by their immunophenotype, which is partly shared with normal HSCs (CD34(+) CD38(-)). However, LSCs also possess unique immunophenotypic features that can be used to distinguish them from HSCs and therapeutically target them. One such unique immunophenotypic marker is CD123, found to be aberrantly expressed in leukemic stem, progenitor, and blast cells. Thus, CD123 is sought as an attractive target to eliminate LSCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available